Your browser doesn't support javascript.
Performance Characteristics of the Abbott BinaxNOW SARS-CoV-2 Antigen Test in Comparison to Real-Time Reverse Transcriptase PCR and Viral Culture in Community Testing Sites during November 2020.
Almendares, Olivia; Prince-Guerra, Jessica L; Nolen, Leisha D; Gunn, Jayleen K L; Dale, Ariella P; Buono, Sean A; Deutsch-Feldman, Molly; Suppiah, Suganthi; Hao, LiJuan; Zeng, Yan; Stevens, Valerie A; Knipe, Kristen; Pompey, Justine; Atherstone, Christine; Bui, David P; Powell, Tracy; Tamin, Azaibi; Harcourt, Jennifer L; Petway, Marla; Bohannon, Caitlin; Folster, Jennifer M; MacNeil, Adam; Salerno, Reynolds; Kuhnert-Tallman, Wendi; Tate, Jacqueline E; Thornburg, Natalie; Kirking, Hannah L; Sheiban, Khalilullah; Kudrna, Julie; Cullen, Theresa; Komatsu, Kenneth K; Villanueva, Julie M; Rose, Dale A; Neatherlin, John C; Anderson, Mark; Rota, Paul A; Honein, Margaret A; Bower, William A.
  • Almendares O; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Prince-Guerra JL; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Nolen LD; Laboratory Leadership Service, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Gunn JKL; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Dale AP; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Buono SA; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Deutsch-Feldman M; Arizona Department of Health Services, Phoenix, Arizona, USA.
  • Suppiah S; Epidemic Intelligence Service, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Hao L; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Zeng Y; Laboratory Leadership Service, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Stevens VA; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Knipe K; Epidemic Intelligence Service, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Pompey J; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Atherstone C; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Bui DP; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Powell T; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Tamin A; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Harcourt JL; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Petway M; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Bohannon C; Epidemic Intelligence Service, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Folster JM; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • MacNeil A; Epidemic Intelligence Service, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Salerno R; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Kuhnert-Tallman W; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Tate JE; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Thornburg N; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Kirking HL; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Sheiban K; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Kudrna J; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Cullen T; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Komatsu KK; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Villanueva JM; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Rose DA; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Neatherlin JC; COVID-19 Response Team, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
  • Anderson M; Pima County Health Departmentgrid.437380.b, Tucson, Arizona, USA.
  • Rota PA; Pima County Health Departmentgrid.437380.b, Tucson, Arizona, USA.
  • Honein MA; Pima County Health Departmentgrid.437380.b, Tucson, Arizona, USA.
  • Bower WA; Arizona Department of Health Services, Phoenix, Arizona, USA.
J Clin Microbiol ; 60(1): e0174221, 2022 01 19.
Article in English | MEDLINE | ID: covidwho-2097916
ABSTRACT
Point-of-care antigen tests are an important tool for SARS-CoV-2 detection. Antigen tests are less sensitive than real-time reverse transcriptase PCR (rRT-PCR). Data on the performance of the BinaxNOW antigen test compared to rRT-PCR and viral culture by symptom and known exposure status, timing during disease, or exposure period and demographic variables are limited. During 3 to 17 November 2020, we collected paired upper respiratory swab specimens to test for SARS-CoV-2 by rRT-PCR and Abbott BinaxNOW antigen test at two community testing sites in Pima County, Arizona. We administered a questionnaire to capture symptoms, known exposure status, and previous SARS-CoV-2 test results. Specimens positive by either test were analyzed by viral culture. Previously we showed overall BinaxNOW sensitivity was 52.5%. Here, we showed BinaxNOW sensitivity increased to 65.7% among currently symptomatic individuals reporting a known exposure. BinaxNOW sensitivity was lower among participants with a known exposure and previously symptomatic (32.4%) or never symptomatic (47.1%) within 14 days of testing. Sensitivity was 71.1% in participants within a week of symptom onset. In participants with a known exposure, sensitivity was highest 8 to 10 days postexposure (75%). The positive predictive value for recovery of virus in cell culture was 56.7% for BinaxNOW-positive and 35.4% for rRT-PCR-positive specimens. Result reporting time was 2.5 h for BinaxNOW and 26 h for rRT-PCR. Point-of-care antigen tests have a shorter turnaround time than laboratory-based nucleic acid amplification tests, which allows for more rapid identification of infected individuals. Antigen test sensitivity limitations are important to consider when developing a testing program.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Observational study / Prognostic study Limits: Humans Language: English Journal: J Clin Microbiol Year: 2022 Document Type: Article Affiliation country: JCM.01742-21

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Observational study / Prognostic study Limits: Humans Language: English Journal: J Clin Microbiol Year: 2022 Document Type: Article Affiliation country: JCM.01742-21